Drug Discovery and Design Center, State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
University of Chinese Academy of Sciences, Beijing, 100049, China.
Signal Transduct Target Ther. 2024 Mar 6;9(1):54. doi: 10.1038/s41392-024-01758-8.
Respiratory disease caused by coronavirus infection remains a global health crisis. Although several SARS-CoV-2-specific vaccines and direct-acting antivirals are available, their efficacy on emerging coronaviruses in the future, including SARS-CoV-2 variants, might be compromised. Host-targeting antivirals provide preventive and therapeutic strategies to overcome resistance and manage future outbreak of emerging coronaviruses. Cathepsin L (CTSL) and calpain-1 (CAPN1) are host cysteine proteases which play crucial roles in coronaviral entrance into cells and infection-related immune response. Here, two peptidomimetic α-ketoamide compounds, 14a and 14b, were identified as potent dual target inhibitors against CTSL and CAPN1. The X-ray crystal structures of human CTSL and CAPN1 in complex with 14a and 14b revealed the covalent binding of α-ketoamide groups of 14a and 14b to C25 of CTSL and C115 of CAPN1. Both showed potent and broad-spectrum anticoronaviral activities in vitro, and it is worth noting that they exhibited low nanomolar potency against SARS-CoV-2 and its variants of concern (VOCs) with EC values ranging from 0.80 to 161.7 nM in various cells. Preliminary mechanistic exploration indicated that they exhibited anticoronaviral activity through blocking viral entrance. Moreover, 14a and 14b exhibited good oral pharmacokinetic properties in mice, rats and dogs, and favorable safety in mice. In addition, both 14a and 14b treatments demonstrated potent antiviral potency against SARS-CoV-2 XBB 1.16 variant infection in a K18-hACE2 transgenic mouse model. And 14b also showed effective antiviral activity against HCoV-OC43 infection in a mouse model with a final survival rate of 60%. Further evaluation showed that 14a and 14b exhibited excellent anti-inflammatory effects in Raw 264.7 mouse macrophages and in mice with acute pneumonia. Taken together, these results suggested that 14a and 14b are promising drug candidates, providing novel insight into developing pan-coronavirus inhibitors with antiviral and anti-inflammatory properties.
冠状病毒感染引起的呼吸道疾病仍然是全球健康危机。虽然有几种针对 SARS-CoV-2 的特异性疫苗和直接作用的抗病毒药物可用,但它们对未来新兴冠状病毒的疗效,包括 SARS-CoV-2 的变体,可能会受到影响。针对宿主的抗病毒药物提供了预防和治疗策略,以克服耐药性并应对新兴冠状病毒的未来爆发。组织蛋白酶 L (CTSL) 和钙蛋白酶 1 (CAPN1) 是宿主半胱氨酸蛋白酶,在冠状病毒进入细胞和感染相关免疫反应中发挥关键作用。在这里,两种肽拟态 α-酮酰胺化合物 14a 和 14b 被鉴定为针对 CTSL 和 CAPN1 的强效双重靶标抑制剂。人 CTSL 和 CAPN1 与 14a 和 14b 复合物的 X 射线晶体结构显示 α-酮酰胺基团与 CTSL 的 C25 和 CAPN1 的 C115 的共价结合。两者在体外均表现出强大的广谱抗冠状病毒活性,值得注意的是,它们对 SARS-CoV-2 及其关注变体 (VOCs) 表现出低纳摩尔效力,在各种细胞中的 EC 值范围为 0.80 至 161.7 nM。初步的机制探索表明,它们通过阻断病毒进入发挥抗冠状病毒活性。此外,14a 和 14b 在小鼠、大鼠和犬中表现出良好的口服药代动力学特性,在小鼠中安全性良好。此外,14a 和 14b 治疗均显示出针对 K18-hACE2 转基因小鼠模型中 SARS-CoV-2 XBB 1.16 变体感染的强大抗病毒效力。并且 14b 还显示出对 HCoV-OC43 感染的有效抗病毒活性,最终存活率为 60%。进一步评估表明,14a 和 14b 在 Raw 264.7 小鼠巨噬细胞和急性肺炎小鼠中表现出出色的抗炎作用。综上所述,这些结果表明 14a 和 14b 是有前途的药物候选物,为开发具有抗病毒和抗炎特性的泛冠状病毒抑制剂提供了新的见解。